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TheSPOPgene,which encodes anE3ubiquitin ligase
adaptor, is frequently mutated in a number of cancer
types. However, the mechanisms by which SPOP
functions as a tumor suppressor remain poorly un-
derstood. Here,we show that SPOPpromotes senes-
cence, an important tumor suppression mechanism,
by targeting the SENP7 deSUMOylase for degrada-
tion. SPOP is upregulated during senescence. This
correlates with ubiquitin-mediated degradation of
SENP7, which promotes senescence by increasing
HP1a sumoylation and the associated epigenetic
gene silencing. Ectopic wild-type SPOP, but not
its cancer-associated mutants, drives senescence.
Conversely, SPOP knockdown overcomes senes-
cence. These phenotypes correlate with ubiquitina-
tion and degradation of SENP7 and HP1a sumoyla-
tion, subcellular re-localization, and its associated
gene silencing. Furthermore, SENP7 is expressed
at higher levels in prostate tumor specimens with
SPOP mutation (n = 13) compared to those with
wild-type SPOP (n = 80). In summary, SPOP acts
as a tumor suppressor by promoting senescence
through degrading SENP7.INTRODUCTION
Speckle-type POZ protein (SPOP) is a bric-a-brac-tramtrack-
broad/poxvirus and zinc finger (BTB/POZ) domain protein that
functions as an adaptor for the E3 ubiquitin ligase cullin 3. Recent
genome-wide next-generation sequencing studies have re-
vealed that SPOP is frequently mutated in a number of cancer
types such as prostate and endometrial (Barbieri et al., 2012;
Berger et al., 2011; Le Gallo et al., 2012). These findings suggest
that SPOP is a putative tumor suppressor. SPOP binds to itsCell Repsubstrates via its N-terminal meprin and traf homology (MATH)
domain (Zhuang et al., 2009), whereas it interacts with cullin 3
through the BTB domain at its C terminus (Pintard et al., 2003;
Xu et al., 2003). SPOP mutations observed in human cancers
are clustered in its substrate binding MATH domain (Barbieri
et al., 2012; Berger et al., 2011), suggesting thatSPOPmutations
may promote cancer via altering the function of its substrates.
Indeed, SPOP mutations correlate with changes in the ubiquitin
landscape in prostate cancer (Theurillat et al., 2014). Despite the
fact that a number of SPOP substrates have been described
(such as Ci/Gli, macroH2A, Daxx, SRC3, AR, and DEK; An
et al., 2014; Herna´ndez-Mun˜oz et al., 2005; Kwon et al., 2006;
Li et al., 2014; Theurillat et al., 2014; Zhang et al., 2006), the
mechanistic basis by which SPOP functions as a tumor suppres-
sor remains poorly understood.
Cellular senescence is a state of stable cell growth arrest
(Pe´rez-Mancera et al., 2014). It is an important tumor suppres-
sion mechanism by halting the progression of cancer pro-
genitor cells harboring the initial oncogenic hits. Oncogenic
signaling triggers senescence via mechanisms such as forma-
tion of senescence-associated heterochromatin foci (SAHF),
which are specialized domains of facultative heterochromatin
that contribute to senescence by helping silence proliferation-
promoting genes (such as the E2F target genes; Narita et al.,
2003). Heterochromatin markers such as heterochromatin pro-
tein 1 (HP1) proteins are components of SAHF and are associ-
ated with the promoters of the proliferation-promoting genes in
senescent cells (Narita et al., 2003). Activation of these signaling
pathways cultivates the expression of markers of senescence
such as an increased senescence-associated b-galactosidase
(SA-b-gal) activity (Dimri et al., 1995).
Small ubiquitin-likemodifiers (SUMO) is a dynamic post-trans-
lational protein modification that regulates the function and
subcellular localization of its target proteins (Cuben˜as-Potts
and Matunis, 2013). SUMO has been implicated in regulating
senescence (Bischof et al., 2006; Li et al., 2006; Yates et al.,
2008). SUMO is conjugated to its targets by SUMO-conjugating
machinery, whereas removal of SUMO is performed by a class
of enzymes called sentrin/SUMO-specific proteases (SENP)orts 13, 1183–1193, November 10, 2015 ª2015 The Authors 1183
Figure 1. SPOP Is Upregulated during
Senescence
(A) IMR90 primary human fibroblasts were infected
with retrovirus encoding control or RAS to induce
senescence. Drug-selected cells were stained for
SA-b-gal activity, labeled with BrdU for 30 min, or
stained for cyclin A expression at day 8. Arrows
point to examples of positive cells for the indicated
markers. The scale bar represents 10 mm.
(B) Same as (A) but quantified for SA-b-gal stain-
ing, SAHF, BrdU, and cyclin A-positive cells in
control and RAS-infected cells. A total of 200 cells
were examined for each of the indicated groups.
Error bars represent mean of three independent
experiments with SD. *p < 0.01.
(C) Same as (A) but examined for expression of
SPOP, RAS, and b-actin by immunoblotting.
(D) Time course for senescence markers such as
SA-b-gal activity and SAHF formation and the cell
proliferation marker BrdU incorporation in control
and RAS-infected IMR90 cells. Mean of three in-
dependent experiments with SD is shown.
(E and F) Same as (D) but examined for expres-
sion of SPOP, RAS, p21, cyclin A, and b-actin by
immunoblotting at the indicated time points.
(G) Same as (A), but the RAS-infected cells were
treatedwithorwithout5mMp38 inhibitorSB203580
for 24 hr before harvesting cells for immunoblotting.
The expression of SPOP, RAS, and phospho-MAP-
kinase-activated protein kinase 2 (p-MAPKAPK2),
a direct target of p38 kinase, in the indicated cells
was examined by immunoblotting. b-actin expres-
sion was used as a loading control.through their isopeptidase activity (Mukhopadhyay and Dasso,
2007).Here,we report that SPOPepigenetically promotes senes-
cence by ubiquitin-mediated degradation of SENP7, which
facilitates HP1a-associated gene silencing via its sumoylation.
Our studies indicate that SPOP acts a tumor suppressor by pro-
moting cellular senescence.
RESULTS
SPOP Is Upregulated during Senescence
To determine whether SPOP is regulated during senescence,
IMR90 primary human fibroblasts were induced to undergo
senescence by oncogenic RAS, a well-established model for
studying senescence in normal human cells in vitro (Figure S1A).
The senescence status was confirmed by markers such as
SA-b-gal activity and formation of SAHF (Figures 1A and 1B).
Consistently, cell proliferation markers such as BrdU incorpora-
tion and cyclin A expression were decreased by RAS infection
(Figures 1A and 1B). Interestingly, SPOP was upregulated in se-
nescent cells (Figure 1C). Next, we performed a detailed time
course study for SPOP upregulation and expression of markers
of senescence (such as SA-b-gal activity, SAHF formation, and
upregulation of p21) and cell proliferation markers (including
BrdU incorporation and cyclin A expression). Indeed, SPOP
upregulation was accompanied by induction of markers of
senescence and senescence-associated cell-cycle exit (Figures
1D–1F). SPOP upregulation was also observed during senes-
cence induced by knockdown of the tumor suppressor PTEN1184 Cell Reports 13, 1183–1193, November 10, 2015 ª2015 The Auor extended cell passaging, but not by DNAdamage agent doxo-
rubicin (Figures S1B–S1J). Similar observation was also made in
BJ primary human fibroblasts (Figures S1K–S1M). Together, we
conclude that SPOP is upregulated during senescence.
We next determined the mechanism by which SPOP is upre-
gulated during senescence. Notably, there was no increase in
SPOP mRNA levels in senescent cells (Figure S1N). This sug-
gests that SPOP upregulation occurs at the post-transcriptional
level. Notably, there is evidence to suggest that p38 regulates
SPOP protein stability (Bunce et al., 2008). Thus, we sought to
determine whether SPOP upregulation is dependent upon p38
activity. Toward this goal, we suppressed the p38 activity using
a small molecular inhibitor SB203580. Indeed, SB203580 treat-
ment significantly decreased the levels of SPOP in treated cells
(Figure 1G). Together, we conclude that SPOP is upregulated
at the post-transcriptional level in a p38-dependent manner dur-
ing senescence.
Ectopic Expression of Wild-Type SPOP, but Not Its
Cancer-Associated Mutants, Drives Senescence
Because we observed an upregulation of SPOP during senes-
cence (Figure 1), we determined whether ectopic expression of
wild-type SPOP is sufficient to drive senescence. We ectopically
expressed wild-type SPOP in IMR90 cells (Figure 2A). Indeed,
ectopic SPOP expression induced expression of markers of
senescence such as SA-b-gal activity and upregulation of p53
and p21, whereas it suppressed cell proliferation markers such
as BrdU incorporation, serine 10 phosphorylated histone H3thors
Figure 2. Ectopic Expression of Wild-Type SPOP, but Not Cancer-Associated SPOP Mutants, Induces Senescence and the Associated Cell
Growth Arrest
(A) IMR90 cells were infected with retrovirus encoding wild-type or the indicated cancer-associated mutant SPOP. Six days post-drug selection, the indicated
cells were examined for expression of the indicated proteins by immunoblotting.
(B) Same as (A) but stained for SA-b-gal activity or examined for BrdU incorporation. Arrows point to examples of SA-b-gal- and BrdU-positive cells. The scale bar
represents 10 mm.
(C and D) Quantification of (B). Two hundred cells from each of the indicated groups were examined for expression of SA-b-gal activity (C) or BrdU positivity (D).
Mean of three independents with SD is shown.
(E and F) Same as (A), but 3,000 of each of the indicated cells were seeded into 6-well plates for focus formation assays. Cells were fixed and stained with 0.05%
crystal violet after growing for an additional 10 days (E). The integrated density was quantified using NIH ImageJ software (F).
(G) IMR90 cells were infected with a control retrovirus or one encoding wild-type SPOP together with an shRNA that targets the open reading frame of SPOP or
controls. The cells were examined for expression of the indicated proteins by immunoblotting 6 days post-drug selection.(pS10H3), and cyclin A expression (Figures 2A–2D). Notably,
DNA damage markers such as gH2AX expression and foci
formation were not activated during senescence induced by
SPOP (Figures S2A–S2C). Expression of the known SPOP
substrate macroH2A that is implicated in senescence (Zhang
et al., 2005) was not affected by SPOP expression (Figure 2A).
This suggests that senescence induced by SPOP is medi-
ated by previously unidentified substrates. Consistently, SPOP
induced an apparent cell growth inhibition as determined by
focus formation (Figures 2E and 2F). The observed effects
were specifically due to SPOP overexpression because knock-
down of the ectopic SPOP suppressed the senescence pheno-
type in these cells (Figure 2G; data not shown). The p53 and
pRB pathways play critical roles in senescence (Pe´rez-Mancera
et al., 2014). Consistently, knockdown of either p53 or pRB
impaired senescence induced by SPOP (Figures S2D–S2G).
We conclude that ectopic expression of wild-type SPOP induces
senescence.
We next determined whether SPOPmutants observed in pros-
tate cancers are impaired in senescence induction. We ectopi-
cally expressed two MATH-domain-mutated SPOPs (F102C
and Y87C) that are frequently observed in prostate cancers (Bar-
bieri et al., 2012; Berger et al., 2011; Jones et al., 2014; Le GalloCell Repet al., 2012). Compared with wild-type SPOP, the SPOPmutants
were impaired in senescence induction as determined by a
significant decrease in SA-b-gal activity and p53 and p21
expression (Figures 2A–2C and S2H). Consistently, there was
an increase in cell proliferation markers such as BrdU incorpo-
ration and expression of pS10H3 and cyclin A in cells expressing
SPOP mutants compared with wild-type SPOP (Figures 2A–2D).
Indeed, SPOP-induced growth inhibition was also significantly
impaired by the cancer-associated mutants as determined by
focus formation (Figures 2E and 2F). We conclude that wild-
type SPOP drives senescence, whereas its cancer-associated
mutants are impaired in senescence induction.
SPOP Knockdown Suppresses Senescence
Next, we determined whether SPOP knockdown suppresses
senescence. IMR90 cells were induced to undergo senescence
with oncogenic RAS together with an shRNA to the human
SPOP gene (shSPOP) or control. Indeed, SPOP knockdown
suppressed the expression of senescence markers such as
SA-b-gal activity, SAHF formation, and upregulation of p53 and
p21 (Figures 3A–3C). In contrast, cell proliferation markers
such as cyclin A expression and BrdU incorporation were
significantly increased in shSPOP/RAS cells compared withorts 13, 1183–1193, November 10, 2015 ª2015 The Authors 1185
Figure 3. SPOP Knockdown Suppresses Senescence
(A) IMR90 cells were infected with a retrovirus encoding oncogenic RAS
together with a lentivirus encoding shSPOP or control. Eight days post-drug
selection, the indicated cells were examined for expression of SPOP, cyclin A,
p53, p21, RAS, and b-actin by immunoblotting.
(B) Same as (A) but examined for SA-b-gal activity, BrdU incorporation, or
SAHF formation by DAPI staining for the punctate pattern in cell nuclei. Arrows
point to examples of cells positive for the indicated markers. Arrowheads
indicate SAHF-positive cells. The scale bar represents 10 mm.
(C) Quantitation of (B). Two-hundred cells from each of the indicated groups
were examined for the expression of the indicated markers. Mean of three
independent experiments with SD is shown. *p < 0.01 compared with controls
and **p < 0.01 compared with RAS infected only.
(D) Same as (A). Six days post-drug selection, 3,000 cells from the each of the
indicated groups were seeded in 6-well plates for focus formation assays.
Cells were fixed and stained with 0.05% crystal violet after growing for an
additional 12 days.
(E) Quantification of (D). The integrated intensity of foci form by the indicated
cells was quantified by using the NIH ImageJ software. Mean of three inde-
pendent experiments with SD is shown. *p < 0.01 compared with controls and
**p < 0.01 compared with RAS infected only.RAS-expressing cells (Figures 3A–3C). Consistently, shSPOP
significantly rescued growth inhibition induced by oncogenic
RAS as determined by focus formation (Figures 3D and 3E).
We conclude that SPOP knockdown suppresses RAS-induced
senescence.
SENP7 Is a SPOP Substrate that Is Degraded during
Senescence
Next, we determined the mechanism by which SPOP regulates
senescence. We performed an in silico analysis of proteins that
are putative SPOP substrates based on the SPOP-binding
recognition motif F-p-S-S/T-S/T (F, non-polar residue; p, polar
residue; Zhuang et al., 2009). This analysis revealed that the
deSUMOylase SENP7 contains two SPOP-binding motifs (Fig-
ure 4A). These motifs are unique to SENP7 as the other six mem-
bers of the SENPs (SENP1–3, SENP5–6, and SENP8) do not
contain SPOP-binding motifs (Figures S3A and S3B). In addition,
SENP7 has two isoforms, namely SENP7L and SENP7S (Bawa-1186 Cell Reports 13, 1183–1193, November 10, 2015 ª2015 The AuKhalfe et al., 2012). Notably, only SENP7L, but not SENP7S, con-
tains the SPOP-binding motif (Figure S3C). To validate this anal-
ysis,weperformedco-immunoprecipitation analysis in 293Tcells
ectopically expressing GFP-SPOP and FLAG-SENP7. Indeed,
ectopic SPOP and SENP7 co-immunoprecipitated with each
other (Figure 4B). In addition, we treated senescent IMR90 cells,
inwhich SPOPexpression is induced,with the proteasome inhib-
itor MG132 to prevent potential degradation of SENP7 by the up-
regulated SPOP. Co-immunoprecipitation analysis revealed that
endogenous SPOP co-immunoprecipitated with endogenous
SENP7 (Figure 4C). As a negative control, therewas no co-immu-
noprecipitation between SPOP and SENP1 (Figure 4C).
Next, we determined whether SENP7 is subject to SPOP-
mediated degradation. We co-expressed SENP7 with a titrated
amount of SPOP. Indeed, there was a SPOP dose-dependent
decrease in SENP7 expression (Figure 4D), suggesting that
SPOP promotes SENP7 degradation. The observed decease in
SENP7 protein levels by SPOP was inhibited by the proteasome
inhibitor MG132 (Figure 4D). This supports our hypothesis that
SPOP promotes ubiquitin-mediated SENP7 degradation. To
directly determine the effects of SPOP on SENP7 ubiquitination,
we examined the ubiquitinated levels of SENP7 in cells express-
ing a HA-tagged ubiquitin treated with MG132 to prevent the
proteasome-dependent degradation of ubiquitinated SENP7.
Indeed, there was a dose-dependent increase in ubiquitinated
SENP7 in SPOP-expressing cells (Figure 4E).
Consistent with the hypothesis that SENP7 is a substrate for
SPOP-mediated degradation during senescence, we observed
a decrease in SENP7 expression in senescent IMR90 cells (Fig-
ure 4F). And SPOP knockdown was sufficient to restore SENP7
expression in these cells (Figure 4G), further supporting the idea
that SPOP mediates SENP7 degradation during senescence.
Next, we determined whether SPOP mutants observed in
prostate cancer are impaired in their ability to degrade SENP7.
Indeed, compared with wild-type SPOP that degrades SENP7
efficiently, cancer-associated SPOP mutants were impaired in
SENP7 degradation (Figure 4H). Similar observations were also
made in prostate cancer cell lines (Figure S4). Consistently,
compared with wild-type SPOP, cancer-associated SPOP mu-
tants were impaired in their ability to ubiquitinate SENP7 (Fig-
ure 4I). This correlated with an impaired interaction between
the cancer-associated mutant SPOP and SENP7 (Figure 4J).
Finally, we determined the correlation of SENP7 protein with
SPOP mutational status in prostate tumor specimens. We per-
formed immunohistochemical staining of SENP7 in a series of 80
SPOPwild-typeand13SPOP-mutatedprostate tumorspecimens
(Figure 4K). SENP7 staining was scored as negative (0), weak (1),
intermediate (2), or strong (3). Statistical analysis revealed that
SENP7 is expressed at significantly (p < 0.0001) higher levels in
prostate tumors with SPOP mutations compared to those with
wild-type SPOP (Figure 4L; Table S1). This further supports the
notion that SENP7 is a substrate of SPOP-mediated degradation.
SENP7 Binds to SPOP via Its First SPOP-Binding Motif,
and the Ubiquitination of SENP7 by SPOPDepends upon
Its Interaction with SPOP
Because there are two SPOP-binding motifs on SENP7 (Fig-
ure 4A), we determined whether the binding between SENP7thors
Figure 4. SENP7 Is a SPOP-Binding Sub-
strate that Is Subjected to SPOP-Adaptor-
Mediated Degradation
(A) SENP7 has two putative SPOP-binding
consensus motifs.
(B) Ectopic SPOP and SENP7 interact with each
other. 293T cells were transfected with the indi-
cated GFP-SPOP and/or FLAG-SENP7 plasmids,
and 16 hr post-transfection, cells were treated
with 20 mM MG132 for 8 hr and subjected to co-
immunoprecipitation analysis using the indicated
antibodies or IgG controls. The co-immunopre-
cipitation was analyzed by immunoblotting using
anti-FLAG or anti-GFP antibodies.
(C) Endogenous SPOP interacts with SENP7 in
RAS-infected IMR90 cells. IMR90 cells were in-
fected with a retrovirus encoding oncogenic RAS to
induce SPOP expression. Drug-selected cells were
treated with 20 mM MG132 for 8 hr, and the cells
were subjected to co-immunoprecipitation analysis
usingananti-SPOPantibodyor an isotype-matched
IgG control. The IP’d product was analyzed by
immunoblotting using the indicated antibodies.
(D) SPOP degrades SENP7 expression in a protea-
some-dependent manner. 293T cells were trans-
fected with 100 ng FLAG-SENP7 together with 0,
500,or1,000ngGFP-SPOPplasmids.Sixteenhours
post-transfection, cells were treated with control or
20 mM MG132 for 8 hr and subjected to immuno-
blotting analysis using the indicated antibodies.
(E) SPOP promotes polyubiquitination of SENP7.
293T cells were transfected with the indicated
plasmids, and 16 hr post-transfection, cells were
treated with 20 mM MG132 for 8 hr and subjected
to immunoprecipitation with an anti-FLAG anti-
body for SENP7. The ubiquitination level of SENP7
was analyzed by immunoblotting using an anti-HA
antibody for ubiquitin.
(F) Time course analysis for SENP7 expression
during senescence of IMR90 cells induced by
oncogenic RAS. Expression of SENP7 and b-actin
was examined at the indicated time points by
immunoblotting.
(G) IMR90 cells were co-infected with a retrovirus
encoding for oncogenic RAS together with a lenti-
virus encoding shSPOP or control. Eight days post-
drug selection, cells were examined for expression
of SPOP, SENP7, and b-actin by immunoblotting.
(H) Cancer-associated SPOP mutants lack the
ability to degrade SENP7. 293T cells were trans-
fected with FLAG-SENP7 together with GFP-
tagged wild-type SPOP or the indicated SPOP
mutants. Sixteen hours post-transfection, cells
were subjected to immunoblotting analysis using
the indicated antibodies.
(I) SPOP-induced polyubiquitination of SENP7 is
impaired by cancer-associated SPOP mutants.
293T cells were transfected with the indicated
plasmids, and 16 hr post-transfection, the indi-
cated cells were treated with 20 mM MG132 for
8 hr and subjected to immunoprecipitation with an
anti-FLAG antibody for SENP7. The ubiquitination level of SENP7 was analyzed by immunoblotting using an anti-HA antibody for ubiquitin.
(J) The cancer-associated SPOPmutants are impaired in SENP7 interaction. IMR90 cells were infected with a retrovirus encoding the indicated FLAG-tagged wild-
type or cancer-associated mutant SPOP or control. Drug-selected cells were treated with 20 mMMG132 for 8 hr, and the cells were subjected to co-immunopre-
cipitation analysis usingan anti-FLAGantibody or an isotype-matched IgGcontrol. The IP’d productwas analyzedby immunoblotting using the indicated antibodies.
(K) Examples of SENP7 immunohistochemical staining in SPOP-mutated or wild-type prostate tumor specimens. The scale bar represents 50 mm.
(L) Quantification of SENP7 expression levels in 80 cases of SPOP wild-type and 13 cases of SPOP-mutated prostate tumor specimens.
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Figure 5. Degradation of SENP7 Depends
upon Its Interaction with SPOP via the First
SPOP-Binding Motif in SENP7
(A) The first SPOP-binding motif in SENP7 is
required for its binding to SPOP. 293T cells were
transfected with the indicated plasmids express-
ing GFP-SPOP, FLAG-SENP7 wild-type (WT), first
SPOP-binding motif mutated SENP7 (SENP7 M1)
that SENP7 aas 201–205 LSSSS was mutated
into LAAAS, or second SPOP-binding motif
deleted SENP7 (SENP7 M2) that deleted SENP7
aas 393–397 AGSTT (393–397). Sixteen hours
post-transfection, cells were treated with 20 mM
MG132 for 8 hr and subjected to co-immunopre-
cipitation analysis using the indicated antibodies.
(B) The first SPOP-binding motif in SENP7 is
required for its ubiquitination by SPOP. 293T cells
were transfected with indicated plasmids, and
16 hr post-transfection, cells were treated with
20 mM MG132 and subjected to immunoprecipi-
tation with an anti-FLAG antibody for SENP7. The
ubiquitination level of SENP7 was analyzed by
immunoblotting using an anti-HA antibody for
ubiquitin.
(C) The first SPOP-binding motif in SENP7 is
required for its degradation by SPOP. 293T cells
were transfected with the indicated plasmids.
Sixteen hours post-transfection, cells were sub-
jected to immunoblotting analysis using the indi-
cated antibodies.
(D) Protein abundance of SENP7 wild-type and the
indicated mutants determined by cycloheximide
chase assay. Equal amounts of the indicated
SENP7 wild-type or mutants were transfected into
293T cells, and cells were treated with 50 mg/ml
cycloheximide (CHX) 16 hr post-transfection. Expression of transfected wild-type or the indicated SENP7 mutants was examined by immunoblotting at the
indicated time points after CHX treatment.
(E) The first SPOP-binding motif of SENP7 peptide (aas 201–205 LSSSS; shown in green sticks) bound to SPOP substrate-binding MATH domain (shown in gray
surface representation) is modeled based on two published X-ray crystal structures of substrate bound to the SPOP MATH domain (RCSB ID 3HQM and 3HQL).and SPOP requires one or both binding motifs. Accordingly,
we mutated the two SPOP-binding motifs in SENP7 individually
and ectopically expressed the FLAG-tagged wild-type, binding-
site-1-mutated (M1), or binding-site-2-mutated (M2) SENP7
together with a GFP-tagged SPOP. Co-immunoprecipitation
analysis revealed that both wild-type and SENP7 M2 co-immu-
noprecipitated with SPOP, whereas the SENP7 M1 mutant was
impaired in its interaction with SPOP (Figure 5A). Indeed, ubiq-
uitin analysis showed that both wild-type and M2 mutant
SENP7 were ubiquitinated by ectopic SPOP at comparable
levels, whereas the SENP7 M1 mutant was impaired in its
ubiquitination by SPOP (Figure 5B). Consistently, the expres-
sion levels of both wild-type and SENP7 M2 were reduced
by SPOP, whereas the degradation of SENP7 M1 was impaired
(Figure 5C). Finally, to directly determine the stability of SENP7
wild-type and mutants, we treated cells with the gene transla-
tion inhibitor cycloheximide (CHX) and chased the levels of
wild-type or mutant SENP7 levels over 6 hr. Compared with
wild-type SENP7 and SENP7 M2, which have comparable
degradation rates, there was an increase in protein stability of
the SENP7 M1 mutant (Figure 5D). Further, structure modeling
indicated that the SPOP-binding motif SENP7 peptide fits
nicely into the binding pocket of the SPOP MATH domain (Fig-1188 Cell Reports 13, 1183–1193, November 10, 2015 ª2015 The Auure 5E). We conclude that the first SPOP-binding motif on
SENP7 is required for its binding, ubiquitination, and degrada-
tion by SPOP.
Downregulation of SENP7Promotes Senescence, which
Correlates with an Increase in HP1a Sumoylation and Its
Subcellular Re-localization and the Associated Gene
Silencing
Next, we determined whether SENP7 downregulation drives
senescence of primary IMR90 cells. We knocked down SENP7
expression using an shSENP7 in IMR90 cells. Indeed, SENP7
knockdown induced the expression of markers of senescence
such as SA-b-gal activity, SAHF formation, and upregulation of
p21 and p53 (Figures 6A–6C). Consistently, cell proliferation
markers such as cyclin A expression and BrdU incorporation
were suppressed by SENP7 knockdown (Figures 6A–6C).
Likewise, cell growth was inhibited by SENP7 knockdown as
determined by focus formation (Figures 6D and 6E). Similar
observations were also made in prostate cancer cells (Fig-
ure S5). Knockdown of either p53 or pRB impaired senescence
induced by SENP7 knockdown as evidenced by a decrease in
the SA-b-gal-positive cells (Figures S5F–S5H). Furthermore,
ectopic SENP7 suppressed senescence induced by SPOPthors
Figure 6. SENP7 Knockdown Induces Senescence, which Correlates with an Increase in HP1a Sumoylation and Its Associated Gene
Silencing
(A) IMR90 cells were infected with a lentivirus encoding shSENP7 or control. Day 8 after drug selection, the expression of SENP7, p21, p53, and cyclin A was
examined by immunoblotting. b-actin expression was used as loading control.
(B) Same as (A) but stained for SA-b-gal activity, examined for BrdU incorporation, or stained with DAPI to visualize SAHF. Arrows point to examples of BrdU-
positive cells. The scale bar represents 10 mm.
(C) Quantification of (B). Two hundred cells from each of the indicated groups were examined for SA-b-gal activity or BrdU- or SAHF-positive cells. Mean of three
independent experiments with SD is shown. *p < 0.01.
(D) Same as (A) but examined for focus formation. Three thousand of the indicated cells were seeded in 6-well plates, and cells were fixed and stained with 0.05%
crystal violet after growing for an additional 12 days.
(E) Quantitation of (D). The integrated intensity of foci formed by the indicated cells was measured using the NIH ImageJ software. Mean of three independent
experiments with SD is shown. *p < 0.001.
(F) Same as (A) but examined for HP1a sumoylation. The indicated cells were subjected to immunoprecipitation with an anti-HP1a antibody or an isotype-
matched IgG control using buffers with NEM, an inhibitor of SUMO protease (please see Experimental Procedures for details). The immunoprecipitated samples
were subjected to immunoblotting using an anti-HP1a or anti-SUMO2/3 antibody to detect the sumoylation of HP1a. Asterisks indicated sumoylated HP1a.
(G) SENP7 knockdown promotes SAHF formation and HP1a’s localization into SAHF. Shown is same as (A) but stained for HP1a, PML bodies, and DAPI to
visualize SAHF. Arrows point to the co-localized HP1a and SAHF. Arrowheads indicate the co-localized HP1a and PML bodies. The scale bar represents 10 mm.
(H) Quantification of (F). One hundred cells from each of the indicated groups were examined for SAHF formation, co-localization of HP1a with PML, and co-
localization of HP1a with SAHF. Mean of three independent experiments with SD is shown. *p < 0.05 compared with controls.
(I) SENP7 knockdown enhances HP1a’s association with theCCNA2 gene promoter. Same as (A), but the cells were subjected to chromatin immunoprecipitation
(ChIP) analysis using an anti-HP1a antibody or an isotype-matched IgG control for the CCNA2 promoter. *p < 0.01 compared with controls.
(J) The enhanced association of Sumo2/3 with the CCNA2 gene promoter in cells undergoing senescence, but not quiescence. IMR90 cells were infected with
RAS for 48 hr to induce senescence or made quiescent by contacting inhibition and serum starvation (0.1% serum). The indicated cells were subjected to ChIP
analysis using an anti-SUMO2/3 antibody or an isotype matched IgG control for the CCNA2 gene promoter. Mean of three independent experiments with SD is
shown. *p < 0.01 and #p > 0.05 compared with controls.
(K) Same as (J), but control or RAS-infected cells (48 hr post-infection) were subjected to sequential ChIP analysis using an anti-HP1a antibody followed by an
anti-SUM2/3 antibody for the CCNA2 gene promoter. Mean of three independent experiments with SD is shown. *p < 0.01 compared with controls.overexpression as indicated by a decrease in the SA-b-gal-pos-
itive cells (Figures S5I–S5K). We conclude that SENP7 downre-
gulation promotes senescence.Cell RepNext, we determined the mechanism by which SENP7 down-
regulation promotes senescence. It has previously been demon-
strated that SENP7 binds to HP1a and regulates HP1a’sorts 13, 1183–1193, November 10, 2015 ª2015 The Authors 1189
localization to pericentromeric heterochromatin via its sumoyla-
tion (Maison et al., 2012). SENP7 is a SUMO2/3 chain removal
deSUMOylase (Shen et al., 2009). Because SENP7 knockdown
induces SAHF formation (Figures 6B and 6C), we examined the
effects of SENP7 knockdown on SUMO2/3-modified HP1a
levels. Indeed, compared with controls, there was an increase
in SUMO2/3-modified HP1a in SENP7 knockdown cells (Fig-
ure 6F). Sumoylation is known to regulate target protein subcel-
lular localization including their PML body localization (Cuben˜as-
Potts and Matunis, 2013). In addition, localization of HP1a into
PML bodies is known to facilitate its deposition into SAHF
(Zhang et al., 2005). Thus, we examined the changes in distribu-
tion of HP1a in SENP7 knockdown cells compared with controls.
We observed a significant increase in the localization of HP1a
into SAHF and a significant but mild increase of 1.5-fold in its
localization into PML bodies (Figures 6G and 6H), thus arguing
that HP1a-sumoylation is only weakly participating to PML local-
ization. This suggests that SENP7 downregulation promotes
SAHF formation by increasing HP1a-sumoylation to facilitate
its deposition into SAHF. Consistently, both SPOP ectopic
expression and SENP7 knockdown significantly suppressed
the E2F reporter activity (Figure S5L). Finally, we sought to deter-
mine whether this correlates with the recruitment of HP1a onto
the promoters of proliferation-promoting genes such as the
E2F target gene CCNA2 (encoding for cyclin A), whose expres-
sion is suppressed by SENP7 knockdown (Figure 6A) and is a
known target of HP1a and SAHF-mediated gene silencing
(Narita et al., 2003). We performed chromatin immunoprecipita-
tion (ChIP) analysis for the CCNA2 gene promoter using anti-
bodies to HP1a or an IgG control. Indeed, there was a significant
increase in the association of HP1a with the CCNA2 gene
promoter in SENP7 knockdown cells compared with controls
(Figure 6I). Notably, ChIP analysis revealed that there was a sig-
nificant increase in the association of SUMO2/3 with the CCNA2
promoter during senescence (Figure 6J). However, there is no
enrichment of SUMO2/3 in the CCNA2 promoter in quiescent
cells (Figure 6J). Consistently, sequential ChIP using an anti-
HP1a followed by an anti-SUMO2/3 antibody showed a signifi-
cant enrichment of SUMO2/3-HP1a in the CCNA2 promoter,
but not in the negative control ACTB promoter, compared with
controls (Figures 6K and S5M). In contrast, there is no enrich-
ment of SUMO2/3-HP1a in the CCNA2 promoter in quiescent
cells (Figure S5N). We conclude that SENP7 knockdown pro-
motes senescence, which correlates with an increase in HP1a
sumoylation, subcellular re-localization to SAHF, and its associ-
ated silencing of certain proliferation-promoting genes.
The Effects of SPOP on Senescence Correlate with
Changes in HP1a Sumoylation, HP1a’s SAHF
Localization, and Its Associated Gene Silencing
SPOP knockdown suppressed senescence (Figure 3), which
correlated with an increase in its substrate SENP7 expression
(Figure 7A). Thus, we determined the effects of SPOP knock-
down on HP1a sumoylation, subcellular localization, and its
association with the CCNA2 gene promoter. Compared with
controls, there was an increase in sumoylated HP1a in RAS-in-
fected cells, which correlated with its SAHF localization and its
recruitment on the promoter of the CCNA2 gene (Figures 7B–1190 Cell Reports 13, 1183–1193, November 10, 2015 ª2015 The Au7E). SPOP knockdown caused a decrease in the levels of su-
moylated HP1a in senescent cells (Figure 7B). This correlated
with a decrease in the localization of HP1a to SAHF and its asso-
ciation with the CCNA2 gene promoter (Figures 7C–7E). SPOP
knockdown increased HP1a’s localization into PML bodies (Fig-
ures 7C and 7D). Because SPOP knockdown decreased HP1a
sumoylation due to an increase in SENP7 (Figures 7A and 7B),
this suggests that HP1a sumoylation is important for transloca-
tion of HP1a from PML bodies to SAHF (Zhang et al., 2005).
Notably, HP1a’s association with the promoters of the E2F target
genes such as CCNA2, MCM3, and thymidylate synthase (TS),
but not with a negative control ACTB gene promoter, was
enhanced by wild-type SPOP (Figure 7F). Compared with wild-
type SPOP, cancer-associated SPOP mutants were impaired
in recruitment of HP1a to theCCNA2 gene promoter (Figure 7G).
This correlated with the ability of wild-type, but not mutant,
SPOP in degrading SENP7 and inducing senescence (Figures
2 and 5). Together, these data support a model whereby upregu-
lation of SPOP promotes senescence by degrading SENP7 de-
SUMOylase, which in turn leads to an increase in the physical
presence of sumoylated HP1a at certain proliferation-promoting
genes concomitant with their silencing.
DISCUSSION
Our data support the hypothesis that SPOP functions as a tumor
suppressor by promoting cellular senescence. This is consistent
with the findings from recent genome-wide deep-sequencing
studies that SPOP is mutated in a number of cancer types (Bar-
bieri et al., 2012; Berger et al., 2011; Le Gallo et al., 2012). Coun-
terintuitively, SPOP is also overexpressed in other cancer types
such as clear cell renal cell carcinoma (Liu et al., 2009), where it
acts as a tumorigenic hub (Li et al., 2014). Themolecular basis for
the observed functional differences in different cancer types re-
mains unclear. It is possible that overcoming SPOP-induced
senescence promotes tumorigenesis in cancers where SPOP
is overexpressed. In this context, SPOP’s role in cancer is akin
to that of oncogenes, where oncogene activation induces senes-
cence, whereas bypass of senescence induced by oncogenes
contributes to cancer progression. In cancers with SPOP muta-
tions, cells harboring SPOPmutations are impaired in the senes-
cence tumor suppression mechanism. This contributes to the
development of SPOP-mutated cancers. Thus, SPOP’s role in
cancer is likely context and tumor type dependent.
Our findings demonstrate that SPOP promotes senescence,
which correlates with HP1a-associated gene silencing. This
is due to its ability to degrade SENP7 deSUMOylase, a SPOP
substrate identified in the current study. Consequently,
SENP7 downregulation leads to an increase in sumoylation
levels of HP1a. This has previously been linked to pericentro-
meric localization of HP1a (Maison et al., 2012). In addition,
SENP7 has been shown to promote chromatin relaxation for
homologous recombination DNA repair (Garvin et al., 2013),
which is consistent with the notion that its degradation pro-
motes heterochromatin formation. The ability of SPOP wild-
type and its cancer-associated mutants to induce senescence
correlates with HP1a-associated silencing of certain prolifera-
tion-promoting genes. Together, these data support the notionthors
Figure 7. The Effects of SPOP on Senescence Correlate with HP1a Sumoylation and Its Associated Gene Silencing
(A) IMR90 cells were infectedwith a retrovirus encoding oncogenic RAS together with a lentivirus encoding shSPOP or control. Eight days post-drug selection, the
expression of SPOP, RAS, SENP7, HP1a, and b-actin was examined by immunoblotting in the indicated cells.
(B) Same as (A) but examined for HP1a sumoylation. The indicated cells were subjected to immunoprecipitation with an anti-HP1a antibody or an isotype-
matched IgG control. The IP’d samples were subjected to immunoblotting using an anti-HP1a or anti-SUMO2/3 antibody to examined sumoylated HP1a levels.
Asterisks indicate sumoylated HP1a.
(C) SPOP knockdown suppresses HP1a’s SAHF localization. Shown is same as (A) but stained for HP1a, PMLbodies, andDAPI to visualize SAHF. Arrows point to
examples of colocalized HP1a and SAHF. Arrowheads indicate colocalized HP1a and PML bodies. The asterisk illustrates an example of a PML body with no
HP1a. The scale bar represents 10 mm.
(D) The quantification of (C). Two hundred cells from each of the indicated groups were examined for SAHF formation, co-localization of HP1a with PML, and
co-localization of HP1a with SAHF. Mean of three independent experiments with SD is shown. *p < 0.01 controls versus RAS-infected cells and **p < 0.01 RAS-
infected versus RAS/shSPOP-expressing cells.
(E) Same as (A) but examined for HP1a’s association with the CCNA2 gene promoter by ChIP analysis. The indicated cells were subjected to ChIP analysis using
an anti-HP1a antibody or an isotype-matched IgG control. Mean of three independent experiments with SD is shown. *p < 0.01 controls versus RAS-infected cells
and **p < 0.01 RAS-infected versus RAS/shSPOP-expressing cells.
(F) IMR90 cells expressing wild-type SPOP or control were subjected to ChIP analysis using an anti-HP1a antibody or an isotype-matched IgG control. The
immunoprecipitated DNA was subjected to qPCR analysis using primers that amplify the indicated promoters of E2F target genes such as CCNA2,MCM3, and
TS, whereas the ACTB gene promoter was used as a negative control for analysis. Mean of three independent experiments with SD is shown. *p < 0.05.
(G) SPOPwild-type, but not its cancer-associated mutants, enhances the interaction between HP1a and theCCNA2 gene promoter. Shown is same as (F) but for
the indicated cells subjected to ChIP analysis using an anti-HP1a antibody or an isotype-matched IgG control for the CCNA2 gene promoter. Mean of three
independent experiments with SD is shown. *p < 0.01 compared with controls and **p < 0.01 compared with wild-type SPOP-expressing cells.that epigenetic gene silencing contributes to senescence
induced by SPOP.
SENP7 knockdown induces formation of microscopically
evident SAHF in addition to an increase in HP1a sumoylation
and its localization to proliferation-promoting genes such as
CCNA2 (Figure 6). Despite the fact that we observed an
enhanced interaction between HP1a and the CCNA2 gene pro-
moter, we did not observe formation of microscopically evident
SAHF in SPOP overexpressing cells (data not shown). This is
likely due to the fact that SENP7 acts downstream of SPOP,
thus driving a more-pronounced phenotype as reflected by
visible SAHF formation. Regardless, both SPOP overexpression
and SENP7 knockdown decreases cyclin A expression, which
correlates with HP1a’s recruitment to the CCNA2 gene pro-
moter. Consistently, it has recently been demonstrated that
SENP7 loss induces senescence of breast cancer cells, whereCell RepSENP7 was first linked to HP1a sumoylation-mediated silencing
of E2F target genes (Bawa-Khalfe et al., 2012). These findings
support the hypothesis that SPOP and SENP7 function in the
same pathway at the molecular level.
SPOP is mutated in a number of cancer types and, most
notably, in prostate cancer (up to 13%; Barbieri et al., 2012;
Berger et al., 2011). Primary prostate tumors with SPOP muta-
tions typically lack other genetic changes such as PTEN and
PIK3CA alterations, ETS fusions, or TP53 mutations (Barbieri
et al., 2012). Thus, SPOPmutations represent a distinct subtype
of prostate cancer. Our findings show that SENP7 knockdown
drives senescence of prostate cancer cell lines (Figure S5).
Silencing of proliferation-promoting E2F target genes induces
senescence regardless of p53 and pRB status (Maehara et al.,
2005; Narita et al., 2003). Our data indicate that SENP7 knock-
down is sufficient to directly silence E2F target genes (such asorts 13, 1183–1193, November 10, 2015 ª2015 The Authors 1191
CCNA2), which correlates with gene promoter recruitment of
HP1a (Figure 6). There are no established cancer cell lines that
carry mutations in SPOP (based on cBioportal analysis), which
prevented us from testing the effects of SENP7 knockdown
in SPOP-mutated cells. Regardless, our results suggest that
SENP7 inhibition may be an intervention strategy for SPOP-
mutated cancers. In addition, because SENP7 knockdown in-
duces senescence of SPOP wild-type prostate cancer cell lines
(Figure S5), this suggests that SENP7 inhibition may synergize
with other targeted therapies in prostate cancer. Finally, these
findings also suggest that patients harboring SPOP mutation
might be less sensitive to treatments that are known to induce
senescence.
In summary, we showed that SPOP promotes cellular senes-
cence, an important tumor suppression mechanism, by de-
grading SENP7 deSUMOylase, a SPOP-binding substrate. This
correlates with HP1a-associated epigenetic gene silencing dur-
ing senescence through a relay of ubiquitination and sumoylation
post-transcriptional modifications. These findings establish that
SPOP functions as a tumor suppressor in the context of cellular
senescence and the associated cell growth arrest.
EXPERIMENTAL PROCEDURES
ChIP and Ubiquitinated Protein Analysis
ChIP was performed as previously described (Tu et al., 2013) using rabbit
anti-HP1a antibody (Novus), anti-SUMO2/3 antibody (Abcam), or an isotype-
matched IgG control. Immunoprecipitated DNA was analyzed using SYBR
Green qpcr (SABiosciences) against the indicated gene promoters using
primers as detailed in the Supplemental Information.
For ubiquitinated protein analysis, cells were treated with 20 mM MG132, a
protease inhibitor, for 8 hr to prevent degradation of the ubiquitinated proteins
prior to harvest. For co-immunoprecipitation, cells were harvested with cold
buffer A (10 mM HEPES-KOH [pH 8.0], 10 mM KCl, 1.5 mM MgCl2, 0.34 M
sucrose, 10% glycerol, and 0.5% Triton X-100 [pH 7.5]) supplemented with
Complete Protease inhibitor cocktail (Roche) and 1 mM PMSF for 5 min on
ice and centrifuged at 3,000 rpm at 4C for 5 min to collect the nucleus pellets.
The pellets were then resuspended in lysis buffer (50 mM Tris-HCl [pH 8.0],
1 mM EDTA, 0.5% NP-40, 300 mM NaCl, 10 mM NaF, protease inhibitor
cocktail, and 1 mM PMSF) and rotated at 4C for 20 min. The lysate was
then centrifuged at 12,000 g at 4C for 10 min, and the supernatant was
used for co-immunoprecipitation. The supernatant was incubated with anti-
SPOP, anti-GFP, anti-FLAG antibody, or an IgG control for 3 hr at 4C and sub-
sequently with Protein G Dynabeads (Life Technologies) for 1 hr. The beads
were washed with NETN buffer three times, boiled in Laemmli sample buffer,
and subjected to immunoblotting.
Structure Modeling
A model of the SPOP MATH domain bound to the first SPOP-binding motif
of SENP7 peptide (aas 201–205; LSSSS) was generated using the X-ray
crystal structure of SPOP-substrate complexes RCSB ID 3HQM and
3HQL. The two crystal structures were overlaid in Coot (Emsley et al.,
2010), and the peptide residues were mutated to the corresponding
LSSSS peptide using sequence alignment as a guide. The figure was pre-
pared in PyMOL (The PyMOL Molecular Graphics System; Version 1.5.0.5
Schro¨dinger).
Prostate Tumor Specimens and IHC
Prostate tumor specimens were obtained from Shanghai Changhai Hospital.
Use of these specimens was approved by the Institute Review Board of
Shanghai Changhai Hospital. SPOP mutation status in prostate tumors was
determined as previously described (Blattner et al., 2014) based on an initial
pre-PCR amplification step to enrich the SPOP exons 6 and 7 followed by a1192 Cell Reports 13, 1183–1193, November 10, 2015 ª2015 The Auhigh-resolution melting screen and Sanger sequencing. Paraformaldehyde-
fixed paraffin-embedded tumor samples were deparaffinized, rehydrated,
and subjected to heat-mediated antigen retrieval. For immunohistochemistry
(IHC) analysis, we used UltraSensitive S-P(Rabbit) IHC Kit (KIT-9706; Fuzhou
Maixin Biotech), following themanufacturer’s instructions withminormodifica-
tion. Briefly, the sectionswere incubatedwith 3%H2O2 for 15min at room tem-
perature to quench endogenous peroxidase activity. After incubating in normal
goat serum for 1 hr, sections were treated with primary antibody at 4C over-
night. IHC analysis of tumor samples was performed using primary antibodies
against SENP7 (dilution 1:200; Novus Biologicals; catalog number: NB100-
92106). The sections were then washed three times in PBS and treated for
30 min with biotinylated goat-anti-rabbit IgG secondary antibodies (Fuzhou
Maixin Biotech). After washing three times in PBS, sections were incubated
with streptavidin-conjugated HRP (Fuzhou Maixin Biotech). After washing
three times in PBS for 5 min each, specific detection was developed with
303-diaminobenzidine (DAB-2031; FuzhouMaixin Biotech). Images were taken
by using an Olympus camera and matched software.
Statistical Analysis
GraphPad Prism Version 5.0 was used to perform for statistical analyses. The
Student’s t test was used to determine p values of raw data. p value < 0.05 was
considered as significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.09.083.
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